Explore our corporate updates and press releases below. For the latest news, follow us on LinkedIn.
To learn more about our company, visit our Corporate Overview page. To see our progress toward new answers and disease-centric therapies, visit our Pipeline page or review recent articles and studies on our Publications page.
|05/26/2022||May 2022 Update||Corporate Update|
|05/12/2022||Pharma Boardroom: Cyril Konto, President & CEO – Ichnos Sciences||Media|
|05/09/2022||Ichnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma||Press Release|
|04/27/2022||Law360: Ichnos Sciences’ New GC On Carving Out ‘Creative Time’||Media|
|04/19/2022||Ichnos Sciences Welcomes Ashok Marín As New General Counsel||Press Release|
|04/12/2022||Genetic Engineering & Biotechnology News: Multi-Specific Ab Analytical Strategies||Media|
|03/23/2022||Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting||Press Release|
|03/18/2022||Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference||Press Release|
|03/01/2022||Ichnos Sciences Welcomes Eugene Zhukovsky, Ph.D., as New Chief Scientific Officer||Press Release|
|02/28/2022||Ichnos Sciences Announces Formation of Scientific Advisory Board to Inform Research and Development Strategy in Immuno-Oncology||Press Release|
The link above is provided for your convenience, and Ichnos is not responsible for content, privacy, or security issues associated with your visit to external websites.